Navigation Links
OmniComm Systems, Inc. Experiences Record Year End Results - $18 Million in Signed Contracts for the Year 2008
Date:1/16/2009

FT. LAUDERDALE, Fla., Jan. 16 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture solutions for clinical trials, today announced record breaking results for 2008 in new and repeat business that exceeded original expectations. A record jump of 80% in contracts over 2007 clearly validates OmniComm's position as a major contender in the EDC Marketplace.

"OmniComm has worked hard to build a strong foundation of superior products and services for our customers," said Stephen Johnson, COO of OmniComm. "We recognize the importance of our clients' business and are working diligently to deliver the integrated solutions that they need to succeed. In the very near future, our plans include the introduction of our own IVRS tool, IVRMaster, that will seamlessly integrate with our EDC tool, TrialMaster(R) to offer randomization, ePRO and supply tracking. In early 2009, we will also be releasing our Clinical Data Hub product to offer a more centralized and seamless aggregation of clinical data across multiple systems. This solution will empower our clients to take better control of their data and better leverage core industry standards like CDISC/CDASH, e2b and SDTM."

Added CFO, Ronald Linares, "We are pleased that we were able to increase our revenues during 2008 during what was a difficult year in the macro- economy. More importantly, we have diversified our client mix to include larger Bio-tech firms and have successfully begun deploying our product on a licensed basis."

OmniComm continues to increase its customer base with a strong mix of new customer business coupled with steady, recurring business from its existing loyal customers. The following is a breakdown of business for 2008.

    Milestones for 2008:

    -- 60 New Business Deals Including:
        -- 4 Pharmaceutical Companies
        -- 20 Biotechnology Companies
            -- Including Top 10 Biotech
        -- 11 Medical Device Companies
        -- 7 Academic Institutions
        -- 14 Contract Research Organizations (CROs)
        -- 4 Consulting Projects
    -- Introduced eLearning tool in July of 2007. Over 250 site users have
       successfully completed TrialMaster eLearning certification since the
       initial launch. The company recently released TrialMaster eLearning
       version 1.1, which includes an additional 9 lessons and certification
       focused on training Site Monitors and internal sponsor personnel.
    -- 2 Technology Transitions and 1 Technology Transfer for EDC
    -- Increased employee headcount from 77 to 85 FTEs
    -- 28 CRO Preferred Program Partners
    -- Expanded European office to include help desk support in seven
       languages

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Chicago, Germany, Tula, Russia, California, Maryland, New York, North Carolina and Texas.

Safe Harbor Disclaimer

Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.


'/>"/>
SOURCE OmniComm Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. OmniComm Systems, Inc. Is Fueled by Another Strong Quarter Delivering Electronic Data Capture (EDC) Solutions & Services
2. DAZ Systems, Inc. Thrives in the Clean Energy Industry
3. Plexus Systems, Inc. to Exhibit at BIOMEDevice Medical Technology Conference
4. Avantis Medical Systems, Inc. Announces Key Leadership Appointments
5. CEOs Letter to Shareholders of Imaging Diagnostic Systems, Inc.
6. Concuity Announces Partnership with Financial Healthcare Systems, LLC
7. StemCor Systems, Inc. Awarded NIH SBIR Grant for Bone Marrow Aspiration Platform
8. Solei Systems, Inc., Announces That the Company Is Now Publicly Traded
9. Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Using SelenoExcell(R)
10. Mark Whitacre, Ph.D. Promoted at Cypress Systems, Inc. and a Warner Brothers Movie to Be Filmed About Him
11. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017  ArmaGen, Inc., a privately ... to treat severe neurological disorders, today reported preliminary ... AGT-181, the company,s investigational therapy for the treatment ... mucopolysaccharidosis type I, or MPS I). The initial ... study, presented today at the 13 th ...
(Date:2/16/2017)... DENVER , Feb. 16, 2017 UCHealth ... hospital to utilize LungDirect for pulmonary nodule patient management. ... a nodule, or a spot on the lung, UCHealth ... spent on manual data entry. Stephanie ... been tracking my nodule patients with an Excel spreadsheet, ...
(Date:2/16/2017)... 16, 2017  Rhythm, a biopharmaceutical company ... that result in life-threatening metabolic disorders, today ... mezzanine round of financing with existing investors ... New Enterprise Associates, Pfizer Venture Investments, Third ... investment fund. Rhythm will use the proceeds ...
(Date:2/15/2017)... 15. Februar 2017  Trianni, Inc. („TRIANNI") gab ... (Janssen) eine Lizenzvereinbarung über die Verwendung der The ... Plattform für die Entdeckung monoklonaler Antikörper. ... chimäres Gensegmentdesign aus, das Janssen den Zugang ... bietet und das für die schelle Isolierung vollständig ...
Breaking Biology Technology:
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market ... for Biometrics and Digital Identity".  Acuity characterizes 2017 ... identity when increased adoption reflects a new understanding ... "Biometrics and digital identity are often ... Maxine Most , Principal of Acuity Market ...
(Date:1/23/2017)... , Jan. 23, 2017  The latest mobile ... smartphone prices have dropped dramatically. The quarterly average price ... 2013 to $276 in Q4 2016.  There are now ... price of $116, up from just 28 a year ... According to Maxine Most , Acuity Market ...
(Date:1/18/2017)... , Jan. 18, 2017  In vitro diagnostic ... to mergers and acquisitions (M&A), and Kalorama Information expects ... such acquisitions have been shifting. Generally, uncertainty in reimbursement ... and the U.S. has changed the acquisitions landscape. Instead ... resulted in companies buying partners outside of their home ...
Breaking Biology News(10 mins):